Loading
Cancer Related Molecular Pathways / DNA Repair Mechanisms / Advanced Breast Cancer Therapies · Journal article
Chemmedchem · September 5, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic in vitro study demonstrating that the small molecule RVJB59 covalently binds to Cys141 on two clinically relevant p53 mutant domains (R280K and R273H) and thermally stabilizes R280K. The work is exploratory and raises the hypothesis that RVJB59 may have therapeutic potential in breast cancers with these mutations, but provides no evidence of efficacy in cells, animals, or patients.
In vitro mechanistic study with computational modelling. Purified DNA-binding domains of p53 R280K and R273H mutants; no cells or organisms.. Intervention: RVJB59 (R-tryptophanol isoindolinone derivative) applied to p53 mutant domains.
RVJB59 thermally stabilized R280K mutant p53 in a dose-dependent manner by differential scanning fluorimetry LC–HRMS/MS confirmed covalent binding of RVJB59 to Cys141 in both R280K and R273H mutant DNA-binding domains Computational studies supported stable binding of RVJB59 near Cys141 in both p53 mutants
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This work does not yet support clinical application. Validation in full-length p53, cellular models, and animal studies would be necessary to assess whether RVJB59 restores tumor suppressor function or has therapeutic benefit.
In vitro mechanistic study of a small molecule binding to mutant p53 domains, with no cell-based or clinical data, raising a question about therapeutic potential rather than demonstrating it.
As stated by the source record.
Quoted from the source exactly as published.
This work does not yet support clinical application. Validation in full-length p53, cellular models, and animal studies would be necessary to assess whether RVJB59 restores tumor suppressor function or has therapeutic benefit.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Breast cancer is one of the most common cancers worldwide. Approximately 30%–40% of breast cancers harbor mutations in the TP53 gene, leading to structural and functional alterations in the p53 protein. These changes result in mutant proteins that are unable to perform their canonical tumor suppressor functions and, in many cases, exhibit gain‐of‐function properties, making mutant p53 a highly attractive therapeutic target. Among these mutations, R280K and R273H are two clinically relevant DNA‐binding mutations. In this study, we extended our investigation of the ( R )‐tryptophanol isoindolinone derivative RVJB59 to these two p53 mutants. Differential scanning fluorimetry showed that RVJB59 thermally stabilized the R280K mutant p53 in a dose‐dependent manner. Furthermore, the mechanism of action of RVJB59 was investigated by liquid chromatography coupled with high‐resolution tandem mass spectrometry (LC–HRMS/MS) using the DNA‑binding domains of the R280K and R273H mutants, confirming covalent binding of the compound to Cys141 in both proteins. Computational studies with both p53 mutants suggested that RVJB59 can stably bind in proximity to Cys141, further reinforcing the results obtained by LC–HRMS/MS. Our findings further underscore the potential of RVJB59 for the development of novel therapies for the treatment of breast cancers harboring these mutations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.